Results 51 to 60 of about 11,211 (144)

Evolution of ART Medication Adherence Support and Monitoring Across IeDEA Sites: Results From Three Waves of Consortium‐Wide Site Assessment Surveys, 2017, 2020 and 2023

Journal of the International AIDS Society, Volume 29, Issue 9, September 2026.
ABSTRACT Introduction Since 2013, global HIV treatment guidelines have included recommendations for medication adherence support and monitoring for people on antiretroviral therapy (ART). We examined the implementation of recommended strategies for adherence support and monitoring for adults with HIV through serial cross‐sectional structured surveys ...
Ellen Brazier, Francesca Odhiambo, Jessie K. Edwards, Lauren Zalla, Charles Kasozi, Eugene Messou, Chantel Schreuder, Romanee Chaiwarith, María Fernanda Rodríguez, Irene Ayakaka, Marcel Zannou, Aimee Freeman, Peter Vanes Ebasone, Dina Muktiarti, Aggrey Semeere, Vohith Khol, Ephrem Mensah, Carina Cesar, Frank Tanser, Edwin Sang, Cuong Duy Do, Armel Poda, Annabelle Niyongabo, Yanink Caro Vega, Jonathan Arthur Colasanti, Idiovino Rafael, Patricia Lelo, Gad Murenzi, Denis Nash, the International Epidemiology Databases to Evaluate AIDS (IeDEA)   +29 more
wiley   +1 more source

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy

Southern African Journal of HIV Medicine, 2020
Introduction: The integrase strand transfer inhibitor dolutegravir (DTG) has a high genetic barrier to resistance. Only rare cases of resistance to DTG have been reported when it is used as a component of antiretroviral therapy regimens in treatment ...
Kairoonisha Mahomed, Carole L. Wallis, Liezl Dunn, Shavani Maharaj, Gary Maartens, Graeme Meintjes   +5 more
doaj   +1 more source

An effective stability indicating RP-HPLC method for simultaneous estimation of Dolutegravir and Lamivudine in bulk and their tablet dosage form

Future Journal of Pharmaceutical Sciences, 2020
Background A Simple, sensitive, and specific stability indicating reverse phase HPLC method was developed for simultaneous estimation of Lamivudine and Dolutegravir in bulk and tablet dosage form.
Ramreddy Godela, Sowjanya G
doaj   +1 more source

Understanding Adolescent Anti‐Retroviral Therapy Use in the BREATHER‐Plus Trial: Qualitative Findings From South Africa and Uganda

Journal of the International AIDS Society, Volume 29, Issue 9, September 2026.
ABSTRACT Introduction The BREATHER‐Plus trial was an open‐label, randomized non‐inferiority trial comparing weekends off antiretroviral therapy (ART) (short cycle therapy [SCT]) with daily oral ART (continuous therapy [CT]) for adolescents aged 12–19 years. We present findings from the qualitative sub‐study on the factors influencing trial participants’
Londiwe Shandu, Stella Namukwaya, Tamlyn Carmin Seunanden, Nothando Ngwenya, Moherndran Archary, Cissy Kityo, Deborah Ford, Sarah L. Pett, Adeodata R. Kekitiinwa, Sarah Bernays, Janet Seeley, the BREATHER‐Plus trial team   +11 more
wiley   +1 more source

Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine

Antiviral Therapy
Dolutegravir 50 mg twice daily (BID) dosing is currently recommended in presence of strong inducers of drug metabolism. However, this dosing has been challenged by studies showing similar rates of viral suppression with dolutegravir once daily (QD ...
Micol Pallanza, Paul Thoueille, Myriam Briki, Susana Alves Saldanha, Matthias Cavassini, Catia Marzolini   +5 more
doaj   +1 more source

Identification of a Novel Small Molecule Facilitating HIV Elimination by the “Shock‐And‐Kill” Approach

Journal of Medical Virology, Volume 98, Issue 9, September 2026.
ABSTRACT Antiretroviral therapy (ART) has markedly improved the prognosis of people living with HIV (PLWH); however, latent viral reservoirs remain a major barrier to a cure. The “Shock and Kill” strategy aims to reactivate latent provirus with latency‐reversing agents (LRAs) and subsequently eliminate the infected cells, yet most LRAs characterized to
Yuichiro Hara, Haruki Kitamura, Kouki Matsuda, Chieko Fujisaki, Sayaka Sukegawa, Kosuke Tanimoto, Kenji Maeda, Hiroaki Takeuchi   +7 more
wiley   +1 more source

Prevalence and Correlates of Hyperglycemia Among People Living With HIV and TB on Dolutegravir‐Based Antiretroviral Therapy in Zimbabwe: A Cross‐Sectional Study

Health Science Reports
Background and Aims In low‐ and middle‐income countries, dolutegravir‐based antiretroviral therapy regimens are the preferred first‐line treatment for adults, adolescents, and children with human immunodeficiency virus (HIV).
Tafadzwa Zireva, Cuthbert Musarurwa, Arthur Mazhandu, Brenda Nherera, Shungu Munyati, Justen Manasa, Danai Tavonga Zhou, Donald Vhanda   +7 more
doaj   +1 more source

Dolutegravir-associated hyperglycemia: a narrative review

AIDS Research and Therapy
Dolutegravir is a preferred antiretroviral drug given its high resistance barrier and efficacy; however, reports from sub-Saharan Africa indicate increased hyperglycemia rates among individuals living with HIV on dolutegravir.
Allan Buzibye, Barbara Castelnuovo, Robert C. Bollinger, Joseph Ssebulime, Denis Omali, Daniel Muller, Frank Mulindwa, Eva Laker, Catriona Waitt, Irene Andia, Mohammed Lamorde, Ahmet Hoke, Bernard S. Bagaya, Yukari C. Manabe   +13 more
doaj   +1 more source

Systematic De-escalation of Successful Triple Antiretroviral Therapy to Dual Therapy with Dolutegravir plus Emtricitabine or Lamivudine in Swiss HIV-positive Persons

EClinicalMedicine, 2018
Background: Studies increasingly suggest that the efficacy of certain dual antiretroviral therapy (ART) combinations is equal to triple ART. Increasing concerns among HIV-positive patients and physicians in Switzerland include ART cost and long-term ART ...
Natascha D. Diaco, Claudio Strickler, Stéphanie Giezendanner, Sebastian A. Wirz, Philip E. Tarr   +4 more
doaj   +1 more source

Dolutegravir use is related to lower HTLV-1 proviral load in people co-infected by HIV-1

Communications Medicine
Background Infection by human T-cell lymphotropic virus type 1 (HTLV-1) affects millions of people worldwide and causes severe diseases. To date, no specific treatment is available for HTLV infection. The purpose of this study was to determine the impact
Tatiana Fernandez, María B. Arriaga, Rafaela Mayoral, Eduardo M. Netto, Carlos Brites   +4 more
doaj   +1 more source